Abstract:Cell division cycle 25 (Cdc25) phosphatase is an attractive target for drug discovery. The rapid assembly and in situ screening of focused combinatorial fragment libraries using efficient modular reactions is a highly robust strategy for discovering bioactive molecules. In this study, we have utilized miniaturized synthesis to generate several quinonoid-focused libraries, by standard CuAAC reaction and HBTU-based amide coupling chemistry. Then the enzyme inhibition screening afforded some potent and selective Cdc25s inhibitors. Compound M5N36 (Cdc25A: IC50 = 0.15 +/- 0.05 mu M; Cdc25B: IC50 = 0.19 +/- 0.06 mu M; Cdc25C: IC50 = 0.06 +/- 0.04 mu M) exhibited higher inhibitory activity than the initial lead NSC663284 (Cdc25A: IC50 = 0.27 +/- 0.02 mu M; Cdc25B: IC50 = 0.42 +/- 0.01 mu M; Cdc25C: IC50 = 0.23 +/- 0.01 mu M). Moreover, M5N36 displayed about three-fold more potent against Cdc25C than Cdc25A and B, indicating that M5N36 could act as a relatively selective Cdc25C inhibitor. Cell viability evaluation, western blotting and molecular simulations provided a mechanistic understanding of the activity of M5N36. It showed promising anti-growth activity against the MDA-MB-231 cell line and desirable predicted physicochemical properties. Overall, M5N36 was proven to be a promising novel Cdc25C inhibitor.

Discovery and structural optimization of pyrazole derivatives as novel inhibitors of Cdc25B.

Discovery of Potent and Selective Cdc25 Phosphatase Inhibitors Via Rapid Assembly and in Situ Screening of Quinonoid-focused Libraries

Discovery of Potent 1H-Imidazo[4,5-b]pyridine-based C-Met Kinase Inhibitors Via Mechanism-Directed Structural Optimization.

Design novel inhibitors for treating cancer by targeting Cdc25B catalytic domain with de novo design.

Synthesis and Cdc25B Inhibition Activity of Novel Imidazo[2,1-b][1,3,4]thiadiazole Derivatives

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Synthesis and Cdc25B/PTP1B Inhibitory Activity Evaluation of Novel Acylhydrazone Derivatives Containing Carbazole Moity

Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.

Discovery of New Inhibitors of Cdc25B Phosphatases by Molecular Docking-Based Virtual Screening

Synthesis and Biological Evaluation of N-acylhydrazone Derivatives Containing Benzimidazole Moiety as Cdc25B and PTP1B Inhibitors

Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors

Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors

Structural Optimization of Pyrazolo[1,5-A]pyrimidine Derivatives As Potent and Highly Selective DPP-4 Inhibitors.

Synthesis And Cdc25b/Ptp1b Inhibitory Activity Evaluation Of Novel Carbazole-Based Mono-/Bis-Thiocarbohydrazone Derivatives

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Design, Synthesis and Structure–activity Relationship of 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(1h)-ones As Potent P53-Mdm2 Inhibitors

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors

Structure-based Screening and Optimization of Cytisine Derivatives As Inhibitors of the Menin-Mll Interaction.

Discovering Potent Inhibitors Against C-Met Kinase: Molecular Design, Organic Synthesis and Bioassay